Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, multicenter phase 2 study of the
safety and efficacy of 3-month subcutaneous (SC) REGN1033 (SAR391786) treatment in patients
with sarcopenia.